PTC Therapeutics, Inc.
Methods of administering deflazacort therapy

Abstract:

The disclosure provides a deflazacort therapy comprising, administering to a subject suffering from Duchenne muscular dystrophy (DMD) a fixed dose of deflazacort. Also provided is a deflazacort therapy comprising, increasing the deflazacort dosage when the subject loses ambulation; or, increasing the dosage of deflazacort administered during concomitant administration of a CYP3A4 inducer; or, decreasing the dosage of deflazacort administered during concomitant administration of a CYP3A inhibitor.